FDA approves Watson ANDA for Budesonide inhalation suspension
02:56 EDT 2 Aug 2012 | Pharmaceutical Business Review
Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has won FDA approval for its abbreviated new drug application (ANDA) for Budesonide inhalation suspension 0.25mg/2mL and 0.5mg/2mL unit-dose ampoules.
Original Article: FDA approves Watson ANDA for Budesonide inhalation suspension
More From BioPortfolio on "FDA approves Watson ANDA for Budesonide inhalation suspension"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
